ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

New Therapies Used in Renal Failure

Received: 11 February 2023, **Revised:** 13 March 2023, **Accepted:** 17 April 2023

Rani Ravina[1], Garg Yukta[2], Jindal Diksha[3], Patil H.C[4], Patil R. K[5]
1,2 Pharm.D (Student), Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda
goyalraveena7@gmail.com
3Associate Professor, Department Pharmaceutical Chemistry,AIPBS, AU, Bathinda
4Professor & Principal, Department of Pharmacy Practice, Adesh Institute of Pharmacy & Biomedical Sciences, AU, Bathinda
5Professor, Department of Pharmacy Practice, Adesh Institue of Pharmacy &Biomedical Sciences, AU, Bathinda
rkpatil3014@gmail.com

Keywords:
Renal function, Extracellular, Kidney, Prevalence, metabolic

Abstract
Acute renal failure affects all organ systems, which is characterized by a sudden loss of renal function, and causes abnormalities in the control of acid-base balance, electrolytes, and divalent captions as well as extracellular fluid balance. The absolute mortality rates for ARF acquired in hospitals and intensive care units are roughly 45% and 70%, respectively, despite significant advancements in organ support devices during the previous 20 years.Additionally, the quality of life has been proposed as a beneficial addition to clinical outcome measures because it can independently predict dialysis patients' death and length of hospitalization.There are also chances of differences in the prevalence if there is difference in the survival or lifetime duration if ailment is diagnosed.

1. Introduction

A condition with numerous underlying causes, renal failure has hazardous results on all organ systems. ARF, which is characterized by decrease in glomerular filtration, causes abnormalities in the control of acid-base balance, electrolytes, and divalent captions as well as extracellular fluid balance. However, the hallmarks of ARF include an elevated serum creatinine concentration, buildup of waste products, and frequently a reduction in urine output. The absolute mortality rates for ARF acquired in hospitals and intensive care units are roughly 45% and 70%, respectively, despite significant advancements in organ support devices during the previous 20 years.However, over the past two decades, the demographics of ARF have shifted, with patients typically being older and having a higher intensity of illness according to different scoring systems. The end phase of chronic kidney diseaseis characterized by clear decline in kidney function. The inability of metabolic waste to be removed on its results in electrolyte imbalance and a variety of poisoning symptoms. The incidence rate of ESRD rises yearly as the population ages. Even with ongoing advancements in medical technology, the death rate is still significant. In practical practice, renal replacement therapy is frequently utilized for ESRD.

Electrolyte imbalance and a variety of poisoning symptoms come from metabolic waste not being able to be eliminated on its own. Because of population aging, ESRD incidence rates are increasing annually. Even with continual medical technology improvements, there are still a lot of deaths. In reality, ESRD patients frequently receive renal replacement treatment.

Additionally, the mode of renal replacement therapy affects the quality of life differently. It is a concept that incorporates economic, social, psychological, and physical aspects as crucial measures for assessing the prognosis of ESRD patients. Additionally, the quality of life has been proposed as a beneficial addition to clinical outcome measures because it can independently predict dialysis patients' death and length of hospitalization.

Up until recently, it has been difficult to determine how non-medical elements evaluated by preference-based measures affect standard of living of ESRD subjects. Therefore, to increase life anticipation and

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

improve standard of living, it is essential to identify the appropriate treatment strategy and associated variables. Here, we assessed how three alternative therapies affected the standard of living of ESRD subjects and the associated influencing factors, offering a theoretical framework for the choice of therapeutic approaches.

Extended discussion of CKD criteria is generally irrelevant for clinical practice due to the less prospectivepossibility for patients given the drugs and lack of advanced predictive tools. The criteria could need to be adjusted if further harmful or costly treatment are introduced or if superior indicators of improvement emerge.

Risk Factors

It is divided into two parts:

1. Modifiable through medical treatment or through lifestyle changes risk factors
2. Non – Modifiable risk factor



2. Epidemiology

Main causes of death and suffering in the present century is Chronic Kidney Disease. Subjects such as older patients, women, diabetic and obese patients are found to have higher prevalence of Chronic Kidney Disease. According to recent study 843.6 million has been affected by this ailment in the 2017 year. It has been emerged as the larger problem in countries with lower and medium per capita income. Although it is a non communicable disease but it has been seen as the increasing cause of mortality in the last 20 years. There is presently no significant data on the time required for detection of the Acute Renal Failure if we apply the criteria of chronicity. There is very few data available that studies the prevalence of the Chronic

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

Kidney Disease over time. However increase in the prevalence is not linear. There is increase in the cases of chronic kidney disease but there is prevent control on the hypertension in the past few years.

There are also chances of differences in the prevalence if there is difference in the survival or lifetime duration if ailment is diagnosed.

SYMPTOMS

DIAGNOSIS

In recent studies, it has been studied that glomerular filtration rate and creatinine levels in the serum have curvilinear relation with each other. Due to this condition there has been reduction in detecting the early phases of renal failure. Urinary proteins and the albumin excretion are generally increased whereas glomerular filtration rate is decreased in the scenario of Chronic Kidney Disease.

Some diagnosis include the saliva urea nitrogen levels in determining the presence of chronic kidney disease using the dip stick method. Epidermal growth factor receptor estimation equations utilize factors such as age, gender, ethnicity, and body size as imprecise surrogate measures of muscle mass variance across populations in an attempt to capture the variability in creatinine produced by muscle mass. Other dip stick test are also used which found out the high levels of blood,pus, bacteria and sugar by inserting into the urine.

The growth of the disease and the complications associated with it can be minimized if it is detected early.



ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

STAGES OF KIDNEY DISEASES:

It is divided into five parts that has been given below:



PHASES	FUNCTION
Phase 1	RFT normal and no impairment kidney
Phase 2	Mild impairment
Phase 3	Mild to Moderate Impairment
Phases 4	Moderate to Severe Impairment
Phases 5	Renal Disease

TREATMENT OF CKD

RENIN–ANGIOTENSIN–ALDOSTERONE SYSTEM

Lewis et al. were the first to demonstrate that angiotensin-converting enzyme inhibitors were helpful in delaying the course of diabetic nephropathy in 1993.Several laboratories conducted animal research.They are, however, particularly helpful in reducing the steady decline of GFR in CKD.The disease state mainly examined with these drugs has been diabetic nephropathy. In both kind of diabetes, reducing the speed of growingkidney damage adjoining RAAS suppression are linked to proteinuria stabilization or reduction.These results have been shown in patients with microalbuminuria and

macroalbuminuria.

Diuretic Drugs

Furosemide is a loop diuretic and vasodilator that can reduce metabolism. Furthermore, diuretics may reduce the toxins in the tubules, such as hemoglobin.Furosemide, according to the hemodynamic criterion, should avert the Acute Renal Failure. There is no solid proof that furosemide modifies the natural course of Chronic KidneyFailure in humans. Recent studies have not founded any difference in azotemia or death. However it was believed that thiazide diuretics have loss their efficacy in the low glomerular filtration rate, but recent studies have proved that chlorthalidone reduces blood pressure in subjects with Chronic Kidney Disease

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

S.No.	Class	Drugs		Pharmacokinetics	Bioavailability	Duration of action	Uses
1.	High ceiling diuretics	Furosemide		Furosemide is absorbed orally over 2-3 hours	The Bioavailability of furosemide id 60%	3-6 hours	Edema, Acute pulmonary edema, Cerebral edema, Hypertension, Hypercalcaemia of maliganancy
		Bumetanide		Bumetanide is absorbed orally	Bioavailability is 80-100%	4-6 hours	
		Torasemide		Torasemide is absorbed orallyand more rapid	Bioavailability is 50-90%	4-8 hours	
2.	Thiazide and related diuretics	Hydrochlorothiazide		All thiazides and realted drugs are well absorbed orally.	Bioavailability is 50-75%	6-8 hours	Diabetes insipidus ,Hypercalciuria,Hypertension, Edema
		Chlorthalidone					
		Metolazone					
		Xipamide					
		Indapamide					
		Clopamide					
3.	Carbonic anhydrase inhibition	Acetazolamide		Absorbed orally	Bioavailability is 70-90%	8-12 hours	Glaucoma, To alkalinizethe urine, Mountain sickness, Period paralysis.
3.	Potassium Sparing Diuretics	Aldosterone antagonist	Spironolactone	Highly bound to plasma proteins and complete metabolized in liver to generate active metabolized , is Canrenone	Bioavailability of Aldosterone antagonist is 75%	1-2 hours	Heart failure, Primarry Hyperaldosteronism, Edema,Hypertension
			Eplerenone				
		Renal epithelial sodium channel inhibitors	Triamterene	Incompletely absorbed	Bioavailability of Renal epithelial sodium channel inhibitors is	Triamterene duration of Action 6-8 hours and Amiloride duration of Action 20 hours	
			Amiloride				

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

4.	Osmotic Diuretics	Mannitol	Isosorbide and glycerol	Mannitol not absorbed orally	Bioavailability is	0.5-1.5 hours	Head injury ,stroke, Reduce intraocular or intracranialtensions

3. Lipid-Lowering Therapy

Although higher lipid levels forbid to induce major renal illnessin and of itself, it may give rise to the suggestion of Chronic Kidney Failure. Suggested pathways are similar to the damage events that cause atherosclerosis in other arterial beds. Inter capillary cells are prompted to employ phagocytic cells in the presence of lipids through building of signal proteins. Activated Inter Capillary cells and accumulating phagocytic cells then produce oxygen radical species, which result in oxidatedless solid lipoproteins. It has been demonstrated that oxidized low-density lipoproteins trigger proinflammatory and profibrotic cytokines.

4. Advancement in Therapies

Pirfenidone's

Pirfenidone's an antifibrotic synthetic chemical that seemed as a viable therapy for Chronic Kidney Disease. Precise method of activity is uncertain, pirfenidone's actions appear to be exaggerated by disruptions in the Transforming growth factor beta. Pirfenidone's dramatically reduced Inter capillarynetworkgrowth in a test model of diabetic nephropathy, regardless of changes in glucose levels. Similar effects have been obtained in post-adaptive focal segmental glomerulosclerosis rat models.

Reference

[1] Ammirati, A. L. (2020). Chronic kidney disease. *Revista da AssociaçãoMédicaBrasileira*, *66*, s03-s09.

[2] Beldhuis, I. E., Lam, C. S., Testani, J. M., Voors, A. A., Van Spall, H. G., Ter Maaten, J. M., &Damman, K. (2022). Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. *Circulation*, *145*(9), 693-712.

[3] Ebert, T., Pawelzik, S. C., Witasp, A., Arefin, S., Hobson, S., Kublickiene, K, &Stenvinkel, P. (2020). Inflammation and premature ageing in chronic kidney disease. *Toxins*, *12*(4), 227.

[4] Elhoseny, M., Shankar, K., &Uthayakumar, J. (2019). Intelligent diagnostic prediction and classification system for chronic kidney disease. *Scientific reports*, *9*(1), 9583.

[5] Forbes, A., & Gallagher, H. (2020). Chronic kidney disease in adults: assessment and management. *Clinical Medicine*, *20*(2), 128.

[6] Gur, E., Levy, D., Topaz, G., Naser, R., Wand, O., Kitay-Cohen, Y& Cohen-Hagai, K. (2022). Disease severity and renal outcomes of patients with chronic kidney disease infected with COVID-19. *Clinical and Experimental Nephrology*, *26*(5), 445-452.

[7] Janse, R. J., Fu, E. L., Dahlström, U., Benson, L., Lindholm, B., van Diepen, M & Savarese, G. (2022). Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence. *European Journal of Heart Failure*, *24*(11), 2185-2195.

[8] Liyanage, T., Toyama, T., Hockham, C., Ninomiya, T., Perkovic, V, Woodward, M & Jun, M. (2022). Prevalence of chronic kidney disease in Asia: a systematic review and analysis. *BMJ global health*, *7*(1), e007525.

[9] Levey, A. S. (2022). Defining AKD: the spectrum of AKI, AKD, and CKD. *Nephron*, *146*(3), 302-305.Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. *Kidney International Supplements*, *12*(1), 7-11.

[10] Lv, J. C., & Zhang, L. X. (2019). Prevalence and disease burden of chronic kidney disease. *Renal fibrosis: mechanisms and therapies*, 3-15.

[11] Ma, F., Sun, T., Liu, L., & Jing, H. (2020). Detection and diagnosis of chronic kidney disease using deep learning-based heterogeneous modified artificial neural network. *Future Generation Computer Systems*, *111*, 17-26.

[12] Sundström, J., Bodegard, J., Bollmann, A., Vervloet, M. G., Mark, P. B., Karasik&Tangri, N.

ISSN: 2309-5288 (Print)
ISSN: 2309-6152 (Online)
CODEN: JCLMC4
Journal of Coastal Life Medicine

(2022). Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2· 4 million patients from 11 countries: The CaReMe CKD study. *The Lancet Regional Health–Europe*, *20*.Levey, A. S., Grams, M. E., & Inker, L. A. (2022). Uses of GFR and albuminuria level in acute and chronic kidney disease. *New England Journal of Medicine*, *386*(22), 2120-2128.

[13] Sperati, C. J., Soman, S., Agrawal, V., Liu, Y., Abdel-Kader, K., Diamantidis, C. J& National Kidney Foundation Education Committee. (2019). Primary care physicians' perceptions of barriers and facilitators to management of chronic kidney disease: a mixed methods study. *PloS one*, *14*(8), e0221325.